These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19126937)

  • 41. Tadalafil: in pulmonary arterial hypertension.
    Croxtall JD; Lyseng-Williamson KA
    Drugs; 2010 Mar; 70(4):479-88. PubMed ID: 20205489
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sildenafil for pulmonary hypertension secondary to congenital heart diseases.
    Gupta A; Kerkar P
    Indian Heart J; 2007; 59(4):342-5. PubMed ID: 19126940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension.
    Lichtblau M; Harzheim D; Ehlken N; Marra A; Pinado FP; Grünig E; Egenlauf B
    Lung; 2015 Feb; 193(1):105-12. PubMed ID: 25318865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term inhaled nitric oxide plus phosphodiesterase 5 inhibitors for severe pulmonary hypertension.
    Pérez-Peñate GM; Juliá-Serdà G; Ojeda-Betancort N; García-Quintana A; Pulido-Duque J; Rodríguez-Pérez A; Cabrera-Navarro P; Gómez-Sánchez MA
    J Heart Lung Transplant; 2008 Dec; 27(12):1326-32. PubMed ID: 19059113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension.
    Chau EM; Fan KY; Chow WH
    Int J Cardiol; 2007 Sep; 120(3):301-5. PubMed ID: 17174418
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.
    Sabri MR; Beheshtian E
    Pediatr Cardiol; 2014 Apr; 35(4):699-704. PubMed ID: 24253611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lupus-associated pulmonary hypertension: long-term response to vasoactive therapy.
    Heresi GA; Minai OA
    Respir Med; 2007 Oct; 101(10):2099-107. PubMed ID: 17618103
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Continuous hemodynamic monitoring in patients with pulmonary arterial hypertension.
    Frantz RP; Benza RL; Kjellström B; Bourge RC; Barst RJ; Bennett TD; McGoon MD
    J Heart Lung Transplant; 2008 Jul; 27(7):780-8. PubMed ID: 18582809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Efficacy and safety of sildenafil therapy in pulmonary artery hypertension: a meta-analysis].
    Kuang TG; Wang J; Zhai ZG; Guo XH; Wang C
    Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1021-4. PubMed ID: 17672963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sustained benefit of tadalafil in patients with pulmonary arterial hypertension with prior response to sildenafil: a case series of 12 patients.
    Tay EL; Geok-Mui MK; Poh-Hoon MC; Yip J
    Int J Cardiol; 2008 Apr; 125(3):416-7. PubMed ID: 17407795
    [No Abstract]   [Full Text] [Related]  

  • 51. The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size.
    Sesti C; Florio V; Johnson EG; Kloner RA
    Int J Impot Res; 2007; 19(1):55-61. PubMed ID: 16858368
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension.
    Hori Y; Kondo C; Matsui M; Yamagishi M; Okano S; Chikazawa S; Kanai K; Hoshi F; Itoh N
    Vet J; 2014 Nov; 202(2):334-9. PubMed ID: 25178687
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
    Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
    N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.
    Zimmermann GS; von Wulffen W; Huppmann P; Meis T; Ihle F; Geiseler J; Leuchte HH; Tufman A; Behr J; Neurohr C
    Respirology; 2014 Jul; 19(5):700-6. PubMed ID: 24697923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tadalafil (Adcirca) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2009 Nov; 51(1324):87-8. PubMed ID: 19890245
    [No Abstract]   [Full Text] [Related]  

  • 56. Transition of PH patients from sildenafil to tadalafil: feasibility and practical considerations.
    Shlobin OA; Brown AW; Weir N; Ahmad S; Lemma M; Nathan SD
    Lung; 2012 Oct; 190(5):573-8. PubMed ID: 22797830
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease.
    Kim HS; Park JH; Park SJ; Park JK; Lee HB
    Korean J Intern Med; 2007 Mar; 22(1):37-9. PubMed ID: 17427645
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension.
    Zlupko M; Harhay MO; Gallop R; Shin J; Archer-Chicko C; Patel R; Palevsky HI; Taichman DB
    Respir Med; 2008 Oct; 102(10):1431-8. PubMed ID: 18617379
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinical efficacy of intravenous L-carnitine in patients with right-sided heart failure induced by pulmonary arterial hypertension].
    Xu XQ; Jing ZC; Jiang X; Zhao QH; He J; Dai LZ; Wu WH; Li Y; Yao J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Feb; 38(2):152-5. PubMed ID: 20398563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.
    Udeoji DU; Schwarz ER
    Ther Adv Respir Dis; 2013 Feb; 7(1):39-49. PubMed ID: 23129569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.